Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2006 1
2007 1
2011 2
2015 2
2019 5
2020 4
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS, Thelemann T, Klar R, Kallert SM, Festag J, Buchi M, Hinterwimmer L, Schell M, Michel S, Jaschinski F, Zippelius A. Kashyap AS, et al. Among authors: jaschinski f. J Immunother Cancer. 2019 Mar 12;7(1):67. doi: 10.1186/s40425-019-0545-9. J Immunother Cancer. 2019. PMID: 30871609 Free PMC article.
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC. Cao Y, et al. Among authors: jaschinski f. Nat Commun. 2019 Mar 20;10(1):1280. doi: 10.1038/s41467-019-09263-1. Nat Commun. 2019. PMID: 30894532 Free PMC article.
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R, Michel S, Schell M, Hinterwimmer L, Zippelius A, Jaschinski F. Klar R, et al. Among authors: jaschinski f. Cancer Immunol Immunother. 2020 Jan;69(1):57-67. doi: 10.1007/s00262-019-02438-1. Epub 2019 Dec 4. Cancer Immunol Immunother. 2020. PMID: 31802183
17 results